Radiomics to predict tumor response to combination chemoradiotherapy in squamous cell carcinoma of the anal canal: a preliminary investigation

被引:0
|
作者
Vanzulli, Andrea [1 ,2 ,3 ]
Sciacqua, Lucilla Violetta [1 ]
Patti, Filippo [4 ]
Drebot, Roza [5 ]
Montin, Eros [6 ,7 ]
Lattanzi, Riccardo [6 ,7 ]
Lozza, Laura Anna Maria [4 ]
Villa, Sergio [4 ]
Scaramuzza, Davide [2 ]
机构
[1] Univ Milan, Diag & Intervent Radiol Residency Program, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Diag & Intervent Radiol, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Radiat Oncol, Milan, Italy
[5] Univ Milan, Dept Oncol & Haemato Oncol, Milan, Italy
[6] New York Univ, Bernard & Irene Schwartz Ctr Biomed Imaging, Grossman Sch Med, Dept Radiol, New York, NY USA
[7] New York Univ, Ctr Adv Imaging Innovat & Res CAI2R, Dept Radiol, Grossman Sch Med, New York, NY USA
关键词
Anal canal; Carcinoma (squamous cell); Magnetic resonance imaging; Precision medicine; Radiomics; CANCER; HETEROGENEITY; CHEMOTHERAPY; RADIOTHERAPY; BREAST;
D O I
10.1186/s41747-025-00559-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundUpfront combination chemoradiotherapy (CRT) represents the standard of care for patients affected by stage III squamous cell carcinoma (SCC) of the anal canal, achieving satisfactory results both in terms of overall survival and local disease control. However, a non-negligible fraction of patients obtain incomplete responses, highlighting the need for innovative prognostic tools. We report the preliminary results of a customized radiomic algorithm designed to predict tumor response to CRT in patients affected by SCC of the anal canal.MethodsWe manually annotated pretreatment T2-weighted turbo spin-echo images of 26 consecutive patients with stage III SCC of the anal canal treated with CRT at our institution from 2012 to 2022. Each patient was classified as complete response (CR, 17 patients), or non-complete response (non-CR, 9 patients) based on the absence or presence of residual disease at imaging and endoscopy after treatment. A total of 132 three-dimensional radiomic features were extracted for each patient and fed to a dedicated machine-learning classifier.ResultsModels trained with gray-level co-occurrence matrix features achieved the best performances (accuracy 0.846 +/- 0.064, sensitivity 0.900 +/- 0.122, specificity 0.833 +/- 0.175, area under receiver operating characteristics curve 0.867 +/- 0.055), highlighting a more homogeneous distribution of voxel intensities and lower spatial complexity in non-CR patients.ConclusionOur radiomic tool accurately predicted tumor response to CRT in patients with stage III SCC of the anal canal, highlighting a more homogeneous tissue composition in poor responders.Relevance statementThe more homogeneous radiomic texture observed in non-CR patients may be imputable to a dominant neoplastic clone with a relatively low mitotic index (therefore, limited tissue necrosis), intrinsically more resistant to CRT than faster-proliferating tumors.Key PointA non-negligible fraction of patients with anal SCC respond unsatisfactorily to CRT.Our radiomic model predicted response to CRT based on pretreatment MRI.We observed a more homogeneous tissue composition in poor responders.The slow proliferation of a dominant clone may explain non-CR to CRT.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Definitive Radiotherapy for Squamous Cell Carcinoma of the Anal Canal
    Rabbani, Anna N.
    Zlotecki, Robert A.
    Kirwan, Jessica
    George, Thomas J., Jr.
    Morris, Christopher G.
    Rout, W. Robert
    Mendenhall, William M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (01): : 47 - 51
  • [22] CHEMORADIOTHERAPY OF ANAL CARCINOMA - TUMOR RESPONSE AND ACUTE TOXICITY
    TANUM, G
    TVEIT, KM
    KARLSEN, KO
    ONCOLOGY, 1993, 50 (01) : 14 - 17
  • [23] Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors
    Kapacee, Z. A.
    Susnerwala, S.
    Wise, M.
    Biswas, A.
    Danwata, F.
    Scott, N.
    COLORECTAL DISEASE, 2016, 18 (11) : 1080 - 1086
  • [24] Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
    Mouw, Kent W.
    Cleary, James M.
    Reardon, Brendan
    Pike, Jonathan
    Braunstein, Lior Z.
    Kim, Jaegil
    Amin-Mansour, Ali
    Miao, Diana
    Damish, Alexis
    Chin, Joanna
    Ott, Patrick A.
    Fuchs, Charles S.
    Martin, Neil E.
    Getz, Gad
    Carter, Scott
    Mamon, Harvey J.
    Hornick, Jason L.
    Van Allen, Eliezer M.
    D'Andrea, Alan D.
    CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3214 - 3222
  • [25] Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C
    White, Evan C.
    Goldman, Kelly
    Aleshin, Alexey
    Lien, Winston W.
    Rao, Aroor R.
    RADIOTHERAPY AND ONCOLOGY, 2015, 117 (02) : 240 - 245
  • [26] Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
    White, Evan Carl
    Erickson, Kelly
    Aleshin, Alex
    Lien, Winston Wei
    Rao, Aroor R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
    Shi, Liqiang
    Li, Chengqiang
    Bai, Yaya
    Cao, Yuqin
    Zhao, Shengguang
    Chen, Xiaoyan
    Cheng, Zenghui
    Zhang, Yajie
    Li, Hecheng
    EUROPEAN RADIOLOGY, 2025, 35 (03) : 1594 - 1604
  • [28] How to stage and treat squamous cell carcinoma of the anal canal?
    Ilias, Elias Jirjoss
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2008, 54 (05):
  • [29] Treatment Options in Metastatic Squamous Cell Carcinoma of the Anal Canal
    Eng, Cathy
    Pathak, Priyanka
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (4-6) : 400 - 407
  • [30] Management of Stage I Squamous Cell Carcinoma of the Anal Canal
    Chai, Christy Y.
    Cao, Hop Tran
    Awad, Samir
    Massarweh, Nader N.
    JAMA SURGERY, 2018, 153 (03) : 209 - 215